News | November 14, 2025
Novartis opens radioligand therapy facility in Carlsbad, US
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Transformation to pure-play Innovative Medicines company nears completion
Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Subscribe To Our Newsletter & Stay Updated
